BioAge
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5885 Hollis St Ste 370, Emeryville, Cali...Phone Number
(510) 806-1445Website
www.bioagelabs.comRevenue
$10.3 MillionStock Symbol
BIOAIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
3
2
1
1
1
2
About BioAge
BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses 65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The companys lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAges preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data.Explore more
BioAge Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioAge your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at BioAge
Product Launch: Get notified when BioAge launches new products
Funding: Get notified immidiatlly once BioAge has new funding data
Check if BioAge has recently received funding, and reach out quickly before it becomes old news!
BioAge, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if BioAge is spiking on competitors!
Earning: See what the market has to say on BioAge recently announced quarterly report
Click to see if BioAge had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined BioAge as Masked Content
Find 2 more new buyers
Compare Similar Companies to BioAge
Compare insights from companies similar to BioAge, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
BioAge is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioAge is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioAge.
BioAge financials insights
Gather financial insights about BioAge, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$10.9M
2019
Series B
$23M
2020
Series C
$90M
2024
Series D
$170M
BioAge Tech Stack
A closer look at the technologies used by BioAge
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
BioAge is conducting a three-arm DME proof-of-concept trial for BGE-102, evaluating BGE-102 monotherapy, VEGF monotherapy, and VEGF plus BGE-102 combination therapy, with intraocular IL-6 as the primary endpoint assessed via aqueous humor sampling.
Proof of Concept (POC), Medical Research
Project
BioAge has demonstrated exceptional CNS penetration for BGE-102 in Phase I, achieving a Kp,uu,CSF of 0.7, enabling the program to potentially address a broad range of diseases driven by NLRP3.
Medical Research, Pharmaceuticals
Project
Research & Development, Pharmaceuticals
BioAge News & Media
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
CHENGDU, China, July 14, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factorsBioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema. The company’s chief business officerBioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioAge
Sign Up For FreeTo access detailed company insights
BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses 65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-relat... Read More
